Before School Starts, Train Everyone’s Brains for Allergies and Asthma – Newswise (press release)


Newswise (press release)

Before School Starts, Train Everyone's Brains for Allergies and Asthma
Newswise (press release)
“More than 10 million kids under age 18 have asthma, and one in four suffer from respiratory allergies,” said allergist James Sublett, MD, FACAAI, president of the American College of Allergy, Asthma and Immunology (ACAAI). “Many kids with asthma and …
Benjamin Moore Natura® Now Certified asthma & allergy friendly TMBusiness Wire (press release)
Survey Shows Patients Prefer Full Access to Medications Containing SYS-CON Media (press release)

all 4 news articles »

View full post on asthma – Google News

AstraZeneca starts Phase III program for asthma drug tralokinumab – Pharmaceutical Business Review

AstraZeneca starts Phase III program for asthma drug tralokinumab
Pharmaceutical Business Review
AstraZeneca has started the Phase III program for an investigational human monoclonal antibody tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by the company's global biologics research and …

View full post on asthma – Google News

AstraZeneca starts final-stage tests on severe asthma drug – Reuters


Reuters UK

AstraZeneca starts final-stage tests on severe asthma drug
Reuters
Several firms are racing to develop injectable biotech asthma drugs for patients with severe disease who do not respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion a year. (Reporting by Ben Hirschler, Editing
AstraZeneca Starts Phase III Trial For Asthma Drug TralokinumabLondon South East
AstraZeneca Starts Late-stage Study Of Tralokinumab – Quick FactsRTT News

all 4 news articles »

View full post on asthma – Google News

Dynavax starts Phase I trial of asthma treatment – San Francisco Business Times (blog)

Dynavax starts Phase I trial of asthma treatment
San Francisco Business Times (blog)
The Berkeley company (NASDAQ: DVAX) will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo. If all goes well, 
DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human 4-traders (press release)
Dynavax Initiates First Human Trial in Asthma ProgramMENAFN.COM

all 3 news articles »

View full post on asthma – Google News

Invion starts second phase trial for asthma treatment – Proactive Investors Australia


Proactive Investors Australia

Invion starts second phase trial for asthma treatment
Proactive Investors Australia
Invion (ASX: IVX) has initiated the phase II “NIMA” clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and Infectious Diseases through a cooperative

View full post on asthma – Google News

GlaxoSmithKline starts final-stage tests on severe asthma drug – Fox News

GlaxoSmithKline starts final-stage tests on severe asthma drug
Fox News
Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. Print; Email; Share; Comments; Recommend
GSK Begins Phase lll Program for Mepolizumab in Severe Refractory AsthmaFox Business
GSK starts final-stage tests on severe asthma drugWHTC

all 14 news articles »

View full post on asthma – Google News

GSK starts final-stage tests on severe asthma drug – Reuters

GSK starts final-stage tests on severe asthma drug
Reuters
Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. (Reporting by Ben Hirschler). Health
GSK Begins Phase lll Program for Mepolizumab in Severe Refractory Asthma4-traders

all 5 news articles »

View full post on asthma – Google News